LITHIUM        KEY CLAIMS 
Supporting data
Supported by GSK.
(c) 2004 Excerpta Medica
All rights reserved.
Disclaimer
print this page
 Key claims

Strengths:

  • 'Gold standard' of mood-stabilizing drugs
  • Well-documented efficacy in acute mania and maintenance (less so for bipolar depression)
  • Documented antisuicidal effects
  • Has been used for more than 50 years
  • Inexpensive

Weaknesses:

  • Narrow therapeutic index
  • Difficult to use (monitoring of plasma concentration is required)
  • Poor tolerability profile
  • Poor compliance which may lead to premature relapse
  • Predominantly effective against manic relapse


GSK counterclaim:

Lithium is less effective in treating depression compared with mania (Calabrese JR et al. and Bowden CH et al.).

Guidelines

Supporting trials



  
 Supporting trials
- Prophylactic efficacy of lithium
- Lithium and imipramine in affective episodes
- Lithium serum levels in bipolar maintenance
- Pivotal trial - index depressed*
- Pivotal trial - index manic*
- Lithium maintenance in mood disorders (1)
- Lithium vs carbamazepine in maintenance of bipolar
- Lithium vs carbamazepine in bipolar prophylaxis
- Lithium vs carbamazepine in bipolar maintenance
- Carbamazepine vs lithium in bipolar maintenance
- Carbamazepine and lithium in the MAP study
- Carbamazepine vs lithium and combination
- Valproate and lithium as maintenance therapy (1)
- Valproate and lithium as maintenance therapy (2)
- Valproate and lithium in acute mania
- Valproate vs lithium in suicide risk
- Guidelines

 
home help sitemap acronyms help sitemap home